概括
对治疗性抗体和T细胞受体的专利保护对于市场准入至关重要. 基于Epitope的专利申请面临着不断变化的可专利性标准,需要药物开发商进行战略规划.
科学领域:
- 生物技术是生物技术.
- 知识产权法 知识产权法 知识产权法
- 制药发展 制药发展
背景情况:
- 专利保护对于治疗性抗体和T细胞受体至关重要,以确保在大量研发和监管投资后获得市场独家权.
- 基于Epitope的专利权利要求是保护这些生物制品的关键类别.
- 对表征标题权利要求的司法专利性标准是动态的,并可能发生变化.
研究的目的:
- 阐明与治疗抗体和T细胞受体的表位基专利申请相关的可专利性挑战.
- 提供对当前法律环境和影响表位专利权的司法先例的概述.
主要方法:
- 审查有关法律条款和规章,规范可专利性.
- 分析关键的法庭裁决和关于以表位为基础的索赔的判例.
- 在不同司法管辖区对可专利性标准的比较评估.
主要成果:
- 基于表位的权利要求的可专利性标准由于立法和司法行动而不断变化.
- 在不同的法律管辖区中存在不同的可专利性要求.
- 专利法的不确定性影响了药物独占的战略规划.
结论:
- 开发治疗抗体和T细胞受体的公司必须不断监测并适应不断变化的可专利性标准.
- 战略专利规划对于确保和维持生物制品市场独家权至关重要.
- 了解基于表位的专利法的动态性质对于成功的药物商业化至关重要.
关键词:
抗体是一种抗体.T细胞受体的T细胞受体.标志性 标志性 标志性 标志性patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent patent
相关概念视频
00:42Cross-reactivity
31.1K
Overview
31.1K
01:31Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
02:53Conservative Site-specific Recombination and Phase Variation
6.0K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.0K
02:32Exon Recombination
3.6K
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon...
Exon shuffling follows “splice frame rules.” Each exon...
3.6K
01:19Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K